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The Histopathological Changes Associated with 
Allograft Rejection and Drug Toxicity in Renal 
Transplant Recipients Maintained on FK506 
Clinical Significance and Comparison with Cyc1osporine 
P.S. Randhawa, M.B.B.S., M.D., R. Shapiro, M.D., 
M.L. Jordan, M.D., T.E. Starzl, M.D., Ph.D. and 
A.J. Demetris, M.D. 
The histopathological changes in 51 renal allograft biop-
sies from patients immunosuppressed with FK506 were 
compared with those seen in 30 needle biopsies obtained 
from patients on cyc\osporine. The frequency and sever-
ity of rejection episodes were similar in both groups. Tu-
bular vacuolation and myocyte vacuolation were found to 
be useful morphological markers to monitor short-term 
drug toxicity associated with both drugs. Long-term ad-
ministration of FK506 led to striped interstitial fibrosis 
and arteriolar hyalinosis, similar to that previously docu-
mented for cyc1osporine. One case each of hemolytic ure-
mic syndrome and necrotizing arteriopathy was noted in 
patients receiving FK506. FK506 and cyc1osporine are 
structurally unrelated compounds; hence the parallelism 
observed in their nephrotoxicity profile suggests that the 
interactions of these drugs with renal tissue involves the 
operation of two different initial signal-transducing mech-
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FK506 is a macrolide antibiotic estimated to be 
two to three orders of magnitude more potent as an 
immunosuppressant than cyclosporine (28,35). 
When used as the primary immunosuppressive 
agent in renal transplantation, it lowers or elimi-
nates the need for concurrent steroid administration 
(19,30). It has also been used to salvage allografts 
with acute cellular rejection refractory to cyclo-
sporine, even when OKT3 has been ineffective (9). 
An additional benefit is the lower incidence of hy-
pertension, hypercholesterolemia, and hyperurice-
mia seen in the long-term follow-up of these cases 
(33). The University of Pittsburgh has conducted a 
prospective randomized trial to compare the effi-
cacy of FK506 and cyclosporine in renal transplan-
tation. The purpose of this report is to describe the 
patterns of rejection and drug toxicity observed in 
allograft needle biopsies obtained from these cases. 
Because FK506 will be increasingly used in renal 
transplantation, it is worthwhile for surgical pathol-
ogists to become familiar with these changes. 
MATERIALS AND METHODS 
Thirty-six patients undergoing renal transplanta-
tion at the Presbyterian University Hospital be-
tween February 1990 and May 1991 were randomly 
assigned to receive either FK506 or cyclosporine as 
the primary immunosuppressant. Details of the 
drug administration and therapeutic monitoring pro-
tocols used in these patients have been published 
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35 yr (19-58) 
9M.11F 
CG2. HT 5. OM 6, 
PK 2, HPL 1, 
SLE 3, UN 1 
91 days (7-531) 
Cyclosporine 
16 
38 yr (23-57) 
11M.5F 
CG 7. HT 2. OM 3 
PK 1. UN 3 
31 days (7-140) 
CG. chronic glomerulonephritis; HT. hypertension; OM, di-
abetes mellitus; HPL, hypoplasia; SLE. systemic lupus 
erythematosus; UN, unknown; PK, polycystic kidney. 
(28,30). The demographic characteristics of the 
cases studied are presented in Table 1. 
Renal biopsies were performed in these cases as 
clinically indicated. These were routinely processed 
for paraffin embedding and sectioning at 2 J.1. Two 
haematoxylin eosin stain, one periodic schiff stain, 
one Jones and one trichrome stain were done on 
each biopsy. The presence or absence of the follow-
ing histopathological features was evaluated in each 
biopsy by two of the authors (P.S.R., A.J.D.) with-
out knowledge of the immunosuppressive agents 
used in each case: glomerular cellularity, changes in 
glomerular mesangial matrix and capillary base-
ment membranes, tubular and myocyte vacuola-
tion, tubular necrosis, calcifications, lymphocytic 
infiltrates, edema, hemorrhage, fibrosis, endotheli-
alitis, vessel hyalinoisis, thrombosis, necrotizing ar-
teritis, arteriosclerosis, and arteriolosclerosis. The 
frequency of these changes in the FK506 and cyclo-
sporine groups was compared. 
The diagnosis of acute cellular rejection and a 
grading of its severity was done as follows: (a) min-
imal rejection was defined as sparse lymphoplasma-
cytic infiltrates, tubular damage, and venous lym-
phocytic infiltration that was not readily demonstra-
ble; (b) mild rejection was defined as mUltiple 
discrete foci of activated lymphoplasmacytic infil-
trates with tubuli tis and venous endothelialitis; (c) 
moderate rejection was defined as confluence of 
foci of rejection used to define the mild grade; and 
(d) severe rejection was defined as tubular necrosis, 
tubular loss, and interstitial hemorrhage superim-
posed on a diffuse infiltrate of activated lympho-
cytes. 
An impression of drug toxicity was conveyed to 
the clinicians when (a) tubular or myocyte vacuola-
tion were prominent in the absence of overt features 
of acute rejection; (b) tubulointerstitial calcification 
was seen in the absence of recent acute tubular ne-
crosis or end stage renal disease; (c) striped fibrosis 
was present without any other apparent cause for 
interstitial collagen deposition; or (d) vessel hyali-
nosis was documented in the absence of diabetes 
mellitus, donor disease, or significant clinical hy-
pertension. Statistical comparisons were done using 
the chi-square test with Yates correction or Wilcox-
on's Rank Sum Test. 
RESULTS 
The presence of interstitial infiltrates of activated 
lymphocytes, renal tubular damage, and venous en-
dothelialitis were found to be reliable criteria for 
monitoring acute cellular rejection in FK506-treated 
allografts, as is already well established for patients 
receiving cyclosporine and other immunosuppres-
sive agents. Likewise, conventional criteria, that is, 
extension of the lymphocytic infiltrate into arterial 
walls and the presence of glomerular neutrophilic 
infiltrates, platelet aggregation, and thrombosis, es-
tablished the diagnosis of acute vascular rejection. 
The distribution of different grades of acute cellular 
rejection showed no striking differences between 
the FK506- and cyclosporine-treated groups; how-
ever, this grading system was useful to convey to 
the clinicians the urgency with which a given epi-
sode of rejection needed to be treated. For minimal 
acute cellular rejection, as defined here, patients 
could be simply kept under clinical surveillance; on 
the other hand, with moderate to severe rejection, 
significant augmentation of the level of immunosup-
pression was indicated. 
The percentage of patients experiencing one or 
more episodes of acute cellular allograft rejection 
was higher in the cyclosporine group versus the 
FK506 group (88% vs. 55%, Table 2) despite the 
shorter median follow-up (Table 1) in the former 
group. A comparative study of the evolution of 
chronic vascular rejection and concomitant trans-
TABLE 2. Allograft rejection in study populationa 
FK506 Cyclosporine 
Patients enrolled 20 16 
No. of biopsies 51 30 
Incidence of rejection 55% 88% 
Median onset post- 14 (range, 20 (range, 
transplant (days) 3-19) 4-135) 
Severity of cellular 
rejection 
Minimal 28% 22<'k 
Mild 36% 55% 
Moderate 36% 23% 
a No statistically significant differences were found be-
tween the FK506- and cyclosporine-treated groups. 
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plant glomerulopathy in this cohort of patients 
will require longer follow-up. At the time of this 
analysis, only two FK506-treated patients had de-
veloped significant light microscopic changes of 
this kind, at intervals of 151 and 385 days post-
transplant. 
The median times of onset for the first episode of 
drug toxicity were, respectively, 65 and 19 days 
post-transplant in the FK506 and cyclosporine 
treatment groups. An average of 1.4 episodes of 
drug toxicity was recorded in each FK506-treated 
patient, compared with 1.9 episode per cyclospor-
ine-treated patient. Tubular or myocyte vacuolation 
was a particularly useful index of such episodes of 
drug toxicity (Figs. 1 and 2). Usually, vacuolation 
of both proximal and distal tubules could be dem-
onstrated. The vacuoles were typically small and 
isometric with diameters not exceeding 20% of the 
nuclear diameter. However, focal confluence of 
these smaller vacuoles into larger ones was also 
present in a few microscopic fields. The morphol-
ogy of the vacuoles did not differ in the cyclospor-
ine- and FK506-treated patients. Vacuolation was 
present concomitantly with acute cellular rejection 
in 22 of28 (79%) and in 14 of22 (64%) of biopsies in 
the FK506 and cyclosporine groups, respectively 
(Table 3). Small focal calcifications involving scat-
tered tubular epithelial celis, tubular basement 
membranes, or interstitium were seen in 40% of ep-
isodes of FK506 toxicity and in 15% of episodes of 
cyclosporine toxicity. Striped interstitial fibrosis 
was present in 35% and 23% of these two groups, 
respectively (Fig. 3). Vessel hyalinosis was found in 
40% of FK506-treated patients versus 23% of cyclo-
sporine-treated patients (Fig. 4). Lesions of focal 
glomerular sclerosis were found in two biopsies 
showing other changes compatible with FK506 tox-
icity. 
One case had an arteriopathy involving the inter-
lobular arteries characterized by deposition of a fi-
brinoid material in the intima, accompanied by en-
dothelial prominence, mild intramural lymphocytic 
infiltrates, nuclear pyknosis and fragmentation (Fig. 
5). This patient was a 19-year-old woman who re-
ceived a kidney transplant for endstage renal dis-
ease of undetermined etiology. The biopsy showing 
the arteriopathy was obtained 24 days post-
transplant because of rising blood urea and creati-
nine. The patient responded to a reduction in the 
dosage of FK506 and was discharged from the hos-
pital. A follow-up biopsy 45 days later showed mild 
acute cellular rejection without any residual vascu-
lar lesions. 
Finally, one case of thrombotic microangiopathy 
was observed in a patient on FK506 therapy (Fig. 
6). This case, reported previously (27), was a 36-
year-old woman transplanted for lupus nephritis. A 
hemolytic syndrome developed in the 9th month 
post-transplant. There was no history of any pre-
ceding upper respiratory viral respiratory infection 
or diarrhea, nor was any laboratory evidence of re-
current lupus found. FK506 was discontinued on 
the presumption of drug toxicity and replaced by 
azathioprine. The renal function improved over the 
course of 6 weeks and returned to baseline. Follow-
up renal biopsies were not available. 
DISCUSSION 
FK506 and cyc1osporine are structurally unre-
lated but mechanistically very similar immunosup-
pressive drugs that inhibit T-cell activation E1~1OFK 
The target receptors for these two drugs, FK bind-
ing protein and cyclophilin respectively, both pos-
sess peptidyl-prolyl cis-trans isomerase (PPI-ase) 
activity (6,34). Transcriptional regulation of inter-
TABLE 3. Morphologic criteria of drug toxicity in allograft kidney biopsiesa 

































Hemolytic uremic syndrome 
Chronic rejection, hypertension, 
renal artery stenosis 
Acute tubular necrosis 
Diabetes, hypertension 
Chronic rejection, recurrent 
or de novo glomerulonephritis 
B The frequency of various morphologic findings in FK506-treated patients did not show any statistically significant differences 
compared with the cyclosporine-treated group. 
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(b) 
FIG. 1a,b. (a) The proximal and distal tubules in this patient with clinical FK506 tox-
icity show a fine cytoplasmic vacuolation. (b) In contrast, the vacuolation associated 
with ischemic injury, for example, acute tubular necrosis, is coarse and irregular. 
(Parts c and d shown on p. 64.) 
leukin 2, interleukin 4, and gamma interferon seems 
to be the ultimate molecular basis for the inhibition 
of T-cell-dependent immune interactions observed 
with these drugs (10,38). A preliminary study from 
Pittsburgh found the spectrum of renal allograft pa-
thology seen in patients treated with these two 
drugs to be quite similar (3,4). 
The morphological features of drug toxicity in re-
nal allograft biopsies were somewhat more frequent 
in the cyclosporine-treated patients (1.9 episodes 
per patient) than in patients on FK506 (1.4 episodes 
per patient). Varying degrees of tubular vacuolation 
was frequently demonstrable even in biopsies 
showing acute cellular rejection. If significant lym-
phocytic infiltration and tubular injury are present, 
it can be useful to treat for rejection despite the 
tubular vacuolation. Persistent tubular v'acuolation 
after the rejection has resolved is then managed by 
a reduction in the dosage of FK506 or cyclosporine. 
Other possible causes of isometric tubular vacuola-
tion, such as mannitol or dextran infusions and ex-
posure to radiocontrast media, should be kept in 
mind (5,24). Myocyte vacuolation, when present, 
was accompanied by tubular vacuolation. A thick-
ened medial layer in these vessels suggested an un-
derlying element of vasospasm. The changes were 
generally reversible, regressing over several days as 
the drug dosage was reduced. This is in contrast to 
the smooth-muscle vacuolation seen in patients 
on chemotherapy, which may persist for several 
months after cessation of drug therapy. 
Although the development of peritubular calcifi-
cations was typically a delayed phenomenon, se-
quential allograft biopsies occasionally showed that 
such calcifications could appear and then dissolve 
over several days. It seems that a fairly high turn-
over of calcium can occur in the renal parenchyma. 
These calcifications are probably dystrophic in na-
ture and occur at sites of previous individual tubular 
cell necrosis mediated by drugs. There is evidence 
that ischemia exacerbates drug-induced tubular in-
jury (26,27). Calcifications following pure ischemic 
injury to the tubules are larger and coarser com-
pared with those seen in drug toxicity. 
Striped fibrosis (14,36) is a picturesque term ap-
plied to parallel bands of cortical interstitial fibrosis 
running perpendicular to the renal capsule and sep-
arated by foci of atrophic tubules. The distribution 
(c) 
(d) 
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of the fibrosis suggests that the underlying pathoge-
netic mechanism is an ischemic tubular atrophy and 
fibrous replacement in the watershed zones of renal 
parenchyma lying between adjacent cortical arter-
ies. In the literature on cyclosporine, striped fibro-
sis has implied chronic drug toxicity (22); however, 
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FIG.1c,d. (c) Panoramic electron mi-
crographic view of FKS06-induced 
tubular vacuolization (x3000). (d) At 
higher magnification, the vacuoles 
represent dilatations of the endo-
plasmic reticulum and lysosomal el-
ements (x 13,000). 
it is merely the end result of a vaso-occlusive pro-
cess, so that hypertension, transplant vasculopa-
thy, and renal artery stenosis should be excluded 
before accepting these lesions as evidence of a 
chronic toxic insult to the kidney. The median time 
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FIG. 2. Acute FK506 toxicity resulted in prominent 
myocyte vacuolation in this interlobular artery. The 
patient clinically responded to a reduction in the dose 
of the drug. 
treated patients was 200 days (range, 62-406). 
Striped fibrosis was not always consistently demon-
strable in sequential biopsies from the same patient. 
This can conceivably be a function of the orienta-
tion of the biopsy needle in relation to the parallel 
bands of fibrosis. Alternately, the fibrosis may be 
focal in its distribution and not always sampled. 
Hyalinosis of arterioles and interlobular arteries 
was noted in 10 biopsies from nine FK506-treated 
allografts examined 7 to 531 days post-transplant 
(median, 154 days). Three biopsies were performed 
within 2 weeks of transplantation and probablY 
reflected donor disease. The remaining seven 
biopsies were associated with tubular vacuolation 
(six instances), tubulointerstitial calcifications (four 
instances), and striped fibrosis (three instances). 
Because hypertension was not a significant clin-
ical problem in these patients, it is quite likely 
that FK506 had a role in the pathogenesis of hyali-
nosis in the latter seven cases, as has been previ-
ously reported for cyclosporine (21). Diabetes mel-
litus can produce similar vascular lesions in the 
kidney. 
Thrombotic microangiopathy associated with he-
molytic uremic syndrome developed in one of the 
FK506-treated patients in this series. It is difficult 
to attribute unequivocally the syndrome to FK506 
therapy, but it is worth recalling that glomerular 
capillary thrombosis has been observed in associa-
tion with cyclosporine therapy (13,29,32). The se-
verity of the underlying pathology varies and, as 
illustrated by the case reported here, the allograft 
can potentially recover completely from such an in-
sult. However, in other cases focal segmental thick-
ening or reduplication of the segmental glomerular 
capillary basement membrane, without mesangial 
interposition, can also ensue (22). A number of fa-
talities associated with cyclosporine-induced hemo-
lytic uremic syndrome have been recorded (15,31). 
The differential diagnosis of thrombotic microangi-
opathy includes other causes of hemolytic syn-
drome and acute vascular rejection. 
The patient with FK506-associated arteriopathy 
reported here responded to a reduction in drug dos-
age, and the allograft is functioning well following 
this presumed toxic episode. We have since also 
seen another similar mild, self-limited case. Arteri-
opathy associated with cyclosporine is well docu-
mented (13,32). When associated with marked inti-
mal proliferative lesions, it can lead to graft loss 
(13,32). Milder cases similar to ours have been re-
ported by Mihatsch et al. (23). Experimental toxi-
cology studies, however, have not shown any vas-
cular toxicity of FK506 in the renal arterial tree 
(l,8,37). It is important to stress that the occurrence 
of vascular lesions in renal allografts should not al-
ways be equated with acute drug toxicity. Indeed 
we and others (13) believe that acute vascular re-
jection accounts for most such cases. Before attrib-
uting proliferative arteriopathy to drug therapy, one 
should give due consideration to the possibility that 
acute humoral (vascular) rejection can occur in lym-
phocyte cross match-negative patients, mediated by 
antibodies directed to donor endothelial antigens or 
to other non human leukocyte antigen (HLA) spec-
ificities (2). 
Focal glomerulosclerosis noted in four patients 
receiving FK506 also calls for comment. The native 
kidney disease was essential hypertension in two 
cases, diabetes mellitus in one case, and undeter-
mined in the remaining case. One biopsy had 
changes of chronic transplant glomerulopathy and 
vasculopathy, and focal glomerulosclerosis in this 
instance could have an ischemic basis. In one case, 
a crescenteric lesion with mesangial proliferation 
observed in a previous biopsy suggested de novo 
glomerulonephritis as the cause of the focal scleros-
ing lesion in the glomeruli. In the remaining two 
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(3b) 
FIG. 3. (a) A striped pattern of fibrosis with atrophy of 
the entrapped tubules develops on long-term admin-
istration of FK506, as has been reported for cyclospor-
ine. (b) Focal calcifications in the tubular epithelium 
and interstitium accompany the fibrosis. 
FIG. 4. Deposition of a hyaline material can be ob-
served in arterioles in patients on FK506 therapy not 
known to be diabetic or hypertensive. These changes 
have also been described with cyclosporine therapy 
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FIG. 5. The interlobular artery shown has fibrin depo-
sition, lymphocytes, and nuclear debris in its media. 
The renal function tests in the patients improved as 
the dosage of FK506 was lowered. 
cases, concomitant tubular vacuolation, tubuloin-
terstitial calcification, and striped fibrosis raised the 
possibility that FK506 itself had a role in the devel-
opment of focal segmental glomerulosclerosis. Con-
sistent with this notion, patterns of proteinuria in-
dicative of glomerular injury have been reported in 
patients receiving FK506 (7). Focal segmental 
glomerulosclerosis has been associated with 
chronic cyclosporine therapy (20); but, in general, 
glomerular lesions due to immunosuppressive drugs 
are still poorly understood (22). 
The exact mechanism of FK506-induced renal 
toxicity is not known. A direct antiproliferative ef-
fect of the drug on renal proximal tubular cell lines 
has been shown (17). A reduction of proximal tu-
bule phosphoenolypyruvate carboxylkinase mRNA 
leading to increased fractional citrate seems to oc-
cur in the rat kidney (25). Intrarenal vasoconstric-
tion, possibly mediated by endothelin secretion by 
glomerular mesangial cells, may also be involved 
(16). FK506 is chemically unrelated to cyclosporine 
and has a distinct target receptor. The marked sim-
ilarity in the morphologic correlates of drug toxicity 
observed for these two drugs suggests that the ulti-
mate molecular mechanisms involved in cell injury 
must be closely interlinked. Evidence that these 
mechanisms may not be totally identical comes 
from a report that FK506 is an effective replace-
ment immunosuppressant in cases of cyclosporine 
associated hemolytic uremic syndrome (18). 0 
004 .. 
-.., . 
D~ .... ~~K 
FIG. 6. The glomeruli in this case on FK506 therapy 
show capillary thrombosis and segmental necrosis. 
The patient presented clinically as a hemolytic syn-
drome for which no definite cause could be estab-
lished. 
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